Список литературы

31. Dederichs B., Dietlein M., Jenniches-Kloth B., Schmidt M., Theissen P., Moka D., Schicha H. Radioiodine therapy of Graves’ hyperthyroidism in patients without preexisting ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? Experimen. Clinic. Endocr. Diab., 2006, v. 114, p. 366-370.

32. Eckstein A., Quadbeck B., Mueller G., Rettenmeier A.W., Hoermann R., Mann K., Steuhl P., Esser J. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br. J. Ophthal., 2004, v. 87, p. 773-776.

33. Fung S., Malhotra R., Selva D. Thyroid orbitopathy. Aust. Fam. Phys., 2003, V. 32, P. 615-620.

34. Goldberg R.A., Christenbury J.D., Shorr N. Medial entropion following orbital decompression for dysthyroid ophthalmopathy. Ophthal. Plas. Reconstr.Sur 1988, v. 4, p. 81-85.

35. Kahaly G., Schrezenmeir J., Krause U., Schwikert B., Meuer S., Muller W., Dennebaum R., Beyer J. Ciclosporin and prednisone vs. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Europ. J. Clin. Inves 1986, v. 16, p. 415-422.

36. Kahaly G.J., Petrak F., Hardt J., Pitz S., Egle U.T. Psychosocial morbidity of Graves’ orbitopathy. Clin. Endocr 2005, v. 63, p. 395-402.

37. Kahaly G.J., Pitz S., Hommel G., Dittmar M. Randomized, singleblind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J. Clin. Endocr. Metab., 2005, v. 90, p. 5234-5240.

38. Kahaly G.J., Rosler H.P., Pitz S., Hommel G. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J. Clin. Endocr. Metab., 2000, v.85, p. 102-108.

39. Kauppinen-Makelin R., Karmi A., Leinonen E., Loyttyniemi E., Salonen O., Sane T., Setala K., Viikari J., Heufelder A., Valimaki M. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol, Scand., 2002, v. 80, p. 316-321.

40. Kendler D.L. Lippa J., Rootman J. The initial clinical characteristics of Graves" orbitopathy vary with age and sex. Arch. Ophthalmol., 1993, Vol. 111, p.197-201.

41. Kung A.W., Michon J., Tai K.S., Chan F.L. The effect of somatostatin versus corticosteroids in the treatment of Graves’ ophthalmopathy. Thyroid, 1996, v. 6, p. 381384.

42. Le Moli R., Baldeschi L., Saeed P., Regensburg N., Mourits M.P., Wiersinga W.M. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ophthalmopathy. Thyroid, 2007, v.17, p.357-362.

43. Li J., Xiao Z., Hu X., Li Y., Zhang X., Zhang S., Gong W., Zhao J., Ye X. The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves" Ophthalmopathy Patients. Pharmacol., 2017; v.99 (3-4), p. 144-152.

44. Macchia P.E., Bagattini M., Lupoli G., Vitale M., Vitale G., Fenzi G. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J. Endocrin. Invest, 2001, v. 24, p. 152-158.

45. Marcocci C., Bartalena L., Panicucci M., Marconcini C., Cartei F., Cavallacci G., Laddaga M., Campobasso G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin. Endocr., 1987, v.27, p.33- 42.

46. Marcocci C., Bartalena L., Rocchi R., Marino' M., Menconi F., Morabito E., Mazzi B., Mazzeo S., Sartini M.S., Nardi M., Cartei F., Cionini L., Pinchera A. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J. Clin. Endocr. Metab., 2003, v. 88, p. 3561-3566.

47. Marcocci C., Bartalena L., Tanda M.L., Manetti L., Dell’Unto E., Rocchi E., Barbesino G., Mazzi B., Bartolomei M.P., Lepri P., Cartei F., Nardi M., Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J. Clin. Endocr. Metab, 2001, v.86, p. 3562 - 3567.

48. Marquez S.D., Lum B.L., McDougall I.R., Katkuri S., Levin P.S., MacManus P.S., Donaldson S.S. Long-term results of irradiation for patients with Graves’ ophthalmopathy. Intern. J. Rad. Oncol. Biol. Phys., 2001, v. 51, p. 766-774.

49. McCormick C.D., Bearden W.H., Hunts J.H., Anderson R.L. Cerebral vasospasm and ischemia after orbital decompression for Graves ophthalmopathy. Ophthal. Plast. Reconstr. Surg., 2004, v. 20, p. 347-351.

50. Mourits M.P., Koornneef L., Wiersinga W.M., Prummel M.F., Berghout A., van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J.Ophthal., 1989, v.73, p. 639-644.

51. Mourits M.P., Prummel M.F., Wiersinga W.M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves" ophthalmopathy. Clin Endocrinol (Oxf) 1997, v. 47, p.9-14.

52. Nakahara H., Noguchi S., Murakami N., Morita M., Tamaru M., Ohnishi T., Hoshi H., Jinnouchi S., Nagamadu S., Futami S. Graves’ ophthalmopathy: MR evaluation of 10 Gy vs. 24 Gyirradiation combined with systemic corticosteroids. Radiol 1995, v. 196, p. 857-862.

53. Ng C.M., Yuen H.K.L., Choi K.L., Chan M.K., Yuen K.T., Ng Y.W., Tiu S.C. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med. J., 2005, v. 11, p.322-330.

54. Noth D. Graves" ophthalmopathy: natural history and treatment outcomes. Swiss Med. Wkly., 2001 Vol. 131, P. 603 - 609.

55. O’Hare J.A., Georghegan M. Cigarette smoking as a promoter of Graves’ disease. Europ. J. Intern. Med., 1993, v. 4, p. 289-292.

56. Perros P., Dickinson A.J. Ophthalmopathy. In Werner’s and Ingbar’s The Thyroid - A Fundamental and Clinical Text, edn 9pp 474-487. Eds. LE Braverman & RD Utiger, Philadelphia: Lippincott Williams & Wilkins, 2005 (ch 23B).

57. Perros P., Kendall-Taylor P., Neoh C., Frewin S., Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J. Clin. Endocr. Metab, 2005, v. 90, p.5321-5323.

58. Pfeilschifter J., Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrin 1996, v.45, p. 477 - 481.

59. Prummel M.F., Wiersinga W.M., Mourits M.P., Koornneef L, Berghout A., van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrin., 1989, v.121, (Suppl 2), p. 185-189.

60. Prummel M.F., Wiersinga W.M., Mourits M.P., Koornneef L., Berghout A., van der Gaag R. Effect of abnormal thyroid function on the sever ity of Graves’ ophthalmopathy. Arch. of Int. Med., 1990, v.150, p. 1098-1101.

61. Prummel M.F., Mourits M.P., Berghout A., Krenning E.P., van der Gaag R., Koornneef L., Wiersinga W.M. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. New Engl. J. Med., 1989, v.321, p.1353-1359

62. Prummel M.F., Mourits M.P., Blank L., Berghout L., Koornneef L., Wiersinga W.M. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet, 1993, v.342, p.949-954.

63. Rose G.E. Clinical activity score as a guide in the management of patients with Graves" orbitopathy. Clin Endocr. (Oxf)., 1997, v.47, p.15.

64. Rose G.E., Lund V.J. Clinical features and treatment of late enophthalmos after orbital decompression: a condition suggesting cause for idiopathic ‘imploding antrum’ (silent sinus syndrome). Ophthalmol., 2003, v.110, p. 819-826

65. Rose G.E. Postural visual obscurations in patients with inactive thyroid eye disease; a variant of ‘hydraulic’ disease. Eye, 2006, v. 20, p.1178-1185.

66. Ruchala М, Sawicka-Gutaj Н. Advances in the pharmacological treatment of Graves" orbitopathy. Expert Rev. Clin. Pharmacol., 2016, v. 9, p. 981-989.

67. Sasaki S., Asahara D., Kaneko K., Komatsumoto S. Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic Neuropathy. Am. J. Case Rep., v. 2015, v.16, p. 357-360.

68. Sasim I.V., Berendschot T.T., van Isterdael C., Mourits M.P. Planning health care for patients with Graves" orbitopathy. Graef. Arch. Clin. Exp. Ophthalmol., 2008, v.246, p. 1315-21.

69. Tallstedt L., Lundell G., Terring O., Wallin G., Ljunggren J.-G., Blomgren H., Taube A., Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. New Engl. J. of Med., 1992, v. 326, p.1733-1738.

70. Terwee C.B., Gerding M.N., Dekker F.W., Prummel M.F., Wiersinga W.M. Development of a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy. Br. J. Ophthal., 1998, v. 82, p.773-779.

71. Viebahn M., Marricks M.E., Osterloh M.D. Synergism between diabetic and radiation retinopathy: case report and review. Br. J. Ophthal., 1991, v. 75, p. 29-32.

72. Wakelkamp I.M., Tan H., Saeed P., Schlingemann R.O., Verbraak F.D., Blank L.E., Prummel M.F., Wiersinga W.M. Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmol., 2004, v.111, p.1557-1562.

73. Weetman A.P. Graves’ disease. New Engl. J. of Med., 2000, v. 343, p. 1237-1248.

74. Weissel M., Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe eye disease. Thyroid, 2000, v.10, p. 521

75. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves" ophthalmopathy. Thyroid, 2002, v.12, p. 855-60.

76. Wiersinga W.M., Perros P., Kahaly G.J., Mourits M.P., Baldeschi L. et al. European Group on Graves" Orbitopathy (EUGOGO). Clinical assessment of patients with Graves" orbitopathy: the European Group on Graves" Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol., 2006; v.155, p. 387389

77. Wiersinga W.M., Prummel M.F. Graves’ ophthalmopathy: a rational approach to treatment. Trends in Endocr. and Metab., 2002, v.13, p. 280-287.

78. Wiersinga W.M., Prummel M.F., Terwee C.B. Effects of Graves’ ophthalmopathy on quality of life. J. Endocr. Inves, 2004, v.27, p. 259-264.

79. Wiersinga W.M. Advances in treatment of active, moderate-to-severe Graves" ophthalmopathy. Lanc. Diab. Endocr., 2017, v. 5, p.134-142.

80. Wiersinga W.M. Management of Graves’ ophthalmopathy. Nat ure Clin.Pract. Endocr. and Metab., 2007, v. 3, p. 396-404.

81. Xiaomei Liu, Hui Guo, Juan Liu, Bingyin Shi. Clinical efficacy of combined rituximab treatment in a woman with severe Graves" ophthalmopathy. Exp. Ther. Med., 2016, v.12, p. 1093-10.